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Abstract
Purpose of Review The goal of this paper is to review recent data on biomedical, behavioral, and structural HIV prevention 
interventions for adolescents and young adults.
Recent Findings While it is accepted that HIV prevention interventions must take an integrated approach to achieve maximum 
effectiveness, to date, there have been limited, rigorously evaluated combination prevention interventions for adolescents. There are 
currently a range of effective biomedical, behavioral, and structural approaches that can be integrated into prevention packages to 
address the prevention needs of adolescents, including oral PrEP, male circumcision, rapid HIV testing, numerous behavioral 
interventions, and structural interventions such as cash transfers and community mobilization to address gender-based violence. 
Summary There is still a need for rigorously evaluated, innovative combination prevention packages for adolescents. Prevention 
approaches must take into account the context of young people’s lives and address the multiple levels of influence on their lives 
including parents, partners, and communities.
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Introduction
Overview of Adolescent HIV Epidemic
According to the World Health Organization, AIDS is the
leading cause of death among adolescents in sub-Saharan
Africa and second leading cause for adolescents worldwide
[1]. In 2016 alone, 610,000 young people between the ages of
15 to 24 were newly infected with HIV (https://data.unicef.
org/topic/hivaids/adolescents-young-people/). In sub-Saharan
Africa, girls 15–19 years of age are four to five times more
likely to be infected than their male counterparts with HIV
incidence rates as high as 5–6% among young women <
21 years of age [2]. Without an increase in coverage of effec-
tive prevention and care interventions for adolescents, it is
projected that new adolescent infections will increase 13%
annually leading to 3.5 million new infections by 2030 [3].
Currently, access to prevention and care for adolescents
lags behind what is needed to prevent these pessimistic pro-
jections for adolescent HIV. Most recent data indicate that
only 15% of adolescent girls and 10% of adolescent boys aged
15–19 in sub-Saharan Africa—the region most affected by
HIV—have been tested for HIV in the past 12 months and
received the result of the last test (https://data.unicef.org/topic/
hivaids/adolescents-young-people/). In the USA, the most
recent Youth Risk Behavior Survey data shows that only
10% of high school students had ever been tested for HIV,
yet 30% were currently sexually active and 43% did not use
a condom during last sexual intercourse [4].
Adolescents are at increased risk for HIV due in part to the
multiple co-occurring transitions (i.e., biological, psychologi-
cal) and developmental tasks (e.g., establishing identity) in
this period of the lifespan [5–7], in addition to age and power
imbalances [8, 9], gender inequality, and interpersonal vio-
lence in sexual relationships [10–13]. Among youth, there
are key populations who bear disproportionate burdens of
HIV and are the most vulnerable, including young men who
have sex with men (MSM), transgender youth, those who
inject drugs, and adolescent girls and young women in
Africa. Among young men who have sex with men
(YMSM) in the USA, psychosocial and structural factors
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substantially contribute to age-associated HIV incidence dis-
parities, including depression, substance use, STI infections,
poverty, decreased health care access, and early sexual debut
[14]. For adolescent girls and young women (AGYW), many
of the same drivers of increased risk for young MSM are also
relevant, including poverty, lack of access to school and health
care, depression, and gender power imbalances and sexual
violence.
Definition of Adolescence
Both the World Health Organization and the United Nations
identify adolescence as the period in human growth and de-
velopment that occurs after childhood and before adulthood,
from ages 10 to 19. However, substantial brain development
including the capacity for complex, conceptual thinking con-
tinues into the early 20s [15]. Late adolescence and/or early
adulthood is also marked by social transitions such as
finishing school, finding employment, independent living,
pregnancies, and marriage. For the purposes of this paper,
we use the term “adolescent” to refer those under the age of
majority (i.e., the age at which a child becomes a legal adult)
for the country or state within which they live, and “young
adult” for those over the age of majority due to the distinct
legal and ethical HIV prevention challenges for youth under
age. That said, the developmental similarities between those
under the age of majority and those just over the age of ma-
jority are extensive.
Integrating Prevention Strategies for Maximal Impact
In order to adequately address the HIV epidemic among ado-
lescents and young adults, strategies that integrate biomedical
prevention technologies with behavioral and structural inter-
ventions will be required [16–18]. Behavioral interventions
alone have demonstrated limited efficacy in reducing HIV
incidence among adolescents and young adults, and few tested
interventions have integrated behavioral, structural, and bio-
medical components. In contrast to either a purely biomedical
or behavioral model, a biopsychosocial approach posits that
health is best understood in terms of a combination of biolog-
ical, psychological, and social factors [19, 20]. In this paper,
we review recent data on biomedical, behavioral, and struc-
tural HIV prevention interventions that may be beneficial to
youth (Table 1).
Biomedical HIV Prevention Interventions
The Centers for Disease Control and Prevention (CDC) de-
fines biomedical HIV interventions as medical, clinical, and
public health approaches that moderate biological and physi-
ological factors to prevent HIV infection, reduce susceptibility
to HIV, and/or decrease HIV infectiousness (https://
effectiveinterventions.cdc.gov/en/HighImpactPrevention/
BiomedicalInterventions.aspx). Tremendous scientific and
technological advances in biomedical HIV prevention have
occurred over the past 5 years.
HIV Testing
HIV testing is the gateway to accessing biomedical preven-
tion. While access to rapid and affordable HIV testing has
increased in recent years, adolescents are still one of the pop-
ulations with the lowest testing rates and many vulnerable
adolescent key populations have even lower rates [21, 22]. It
is clear that testing modalities must reach outside of the tradi-
tional clinic setting to reach those at highest risk, including
mobile testing, household testing, and venue-based testing.
Given that the majority of adolescents are often not sexually
active, mass testing of all adolescents may not be a cost-
effective strategy to reach more youth but rather targeted and
innovative testing strategies to reach adolescents in need of
testing are needed. HIV self-testing is another modality that
has been found to be highly acceptable in a number of settings
and offers adolescents a private and convenient way to access
HIV testing [23, 24].
Oral PrEP
In 2012, the US Food and Drug Administration (FDA) ap-
proved the use of once-daily emtricitabine and tenofovir (TDF/
FTC, Truvada®) as oral PrEP for HIV prevention in adults based
on two randomized clinical trials [25, 26]. Subsequent open-
label studies have demonstrated that PrEP reduces the risk of
HIV by over 90% when taken consistently [27, 28].
In these PrEP trials, it has been demonstrated that adherence
to PrEP is crucial for protection against HIV infection and
many young participants struggled to use product daily.
Young MSM ages 18–24 in the iPrEx trial demonstrated lower
PrEP efficacy (28%) compared to older participants (56%), and
youngMSMwere over 3 times less likely to have drug detected
in plasma than were older participants [25]. In two trials that
enrolled a high proportion of young African women, overall
adherence was too low to demonstrate efficacy with tenofovir
detected in less than 30% of plasma samples and PrEP adher-
ence extremely poor in those under age 25 [29, 30].
Two adolescent-focused safety studies of oral PrEP have
recently been completed—Adolescent Trials Network for
HIV/AIDS Interventions 113 (ATN 113) and PlusPills. In the
ATN 113 trial, PrEP was found to be safe and well tolerated
among a cohort of racially/ethnically diverse YMSM ages 15–
17. The majority of participants had adherence levels commen-
surate with HIV protection over the first 12 weeks of the study,
but adherence began to decrease at week 24 and continued to
decline for the remainder of the study. The most common rea-
sons for missing PrEP doses included being away from home,
being too busy, and forgetting. Furthermore, participants who
were worried that PrEP use would make others think they had
HIV were less adherent [31]. The Pluspills study was conduct-
ed in South Africa among adolescent boys and girls, ages 15–
19. In this study, PrEP use was also found to be safe, accept-
able, and tolerable for the Pluspills participants, but adherence
dropped in the second half of the study in a very similar pattern
to ATN 113 [32]. Thus, oral PrEP is safe to use among adoles-
cent populations and appears to be of interest to young people,
but inattention to adherence or inability to adhere may adverse-
ly impact effectiveness, particularly among those who may be
most vulnerable to HIV infection. Several international groups,
including the CDC and the World Health Organization have
distributed recommendations that include special consider-
ations for young adults and adolescents under the age of 18
[33, 34]. Additionally, on May 15, 2018, the US Food and
Drug Administration approved the use of oral TDF/FTC for
adolescents at risk for HIV infection [35].
The ability of adolescents to persist in their use of PrEP
during times of HIV risk is an important consideration as
well. In a recent study in Kenya, 693 AGYW ages 15–29
were enrolled into a PrEP demonstration study. At the end
of 10 months, only 5% of young women were still using
PrEP [36]. Important lessons learned included that such
programs must address other actors in young women’s
lives including partners, parents, family members, and
the community. Lack of community support for PrEP
use and continued stigma around use of PrEP were major
barriers to use and must be addressed in future studies
[36]. In a US cohort study following YMSM, about a
third of those who had tried PrEP discontinued and 79%
of those who discontinued never spoke to a doctor about
doing so. The primary reasons for discontinuation includ-
ed: trouble getting to doctor’s appointments (21.5%), is-
sues related to insurance coverage or loss (20.0%), and
not feeling at risk for HIV (18.5%) [37].
Nonetheless, daily oral TDF/FTC is the only currently ap-
proved PrEP regimen available at this time, thus efforts are
needed to maximize widespread availability and uptake along
with optimization of adherence among youth. In addition, it
needs to be acknowledged that adolescent sexual activity is
often in flux thus lack of use of PrEP over a 12-month period
may asmuch be about lack of sexual activity or partners as it is
about not wanting to use the drug.
Long-Acting Injectable PrEP
In order to address the adherence concerns that plague daily
oral medication regimens, significant resources are being
invested in the discovery and testing of other PrEP technolo-
gies. One approach that aims to provide a more adherence-
friendly schedule is that of long-acting injections. Currently,
only one compound, cabotegravir, has reached efficacy trials.
Cabotegravir is an investigational HIV integrase strand trans-
fer inhibitor that has attributes favorable for both HIV treat-
ment and prevention indications based on its potential for a
high genetic barrier to resistance and a pharmacokinetic pro-
file that allows low-dose, once-daily oral dosing or monthly to
quarterly parenteral dosing using a nanosuspension formula-
tion. Two parallel phase 2b/3 trials of long-acting cabotegravir
are ongoing through the HIV Prevention Trials Network
(HPTN) and aim to compare the safety and efficacy of inject-
able cabotegravir to oral PrEP (TDF/FTC) among MSM and
transgender women (HPTN 083) and women in sub-Saharan
Africa (HPTN 084). Both studies will investigate dosing every
8 weeks and participation is limited to those over the age of 18
[38, 39].
While approval of such a product, if shown to be effica-
cious, is many years away, a few studies have begun to inves-
tigate the potential acceptability of injectable PrEP among
youth. A qualitative study of YMSM and transgender women
in the USA found that participants were generally split on
preference for injectable versus oral PrEP, but they agreed that
injections may be more manageable and better for those who
have adherence difficulties and for those who engage in sex
more frequently [40]. Preferences for product type were also
explored in a randomized, crossover trial of three placebo
prevention products (i.e., daily oral tablet, monthly injections,
and monthly vaginal ring) for young women in sub-Saharan
Africa. Participant ratings were significantly higher for the
injections compared to both the daily tablet and the vaginal
ring [41], indicating that expanded options in HIV prevention
modalities are important for youth.
Microbicides
Microbicides, also considered topical PrEP, are products ap-
plied inside the vagina or rectum (e.g., gels, lubricants, rings)
that are intended to prevent the sexual transmission of HIV,
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while avoiding the potential toxicities of oral or long-acting
systemic PrEP. Pericoital use of vaginal 1% tenofovir (TFV)
gel provided overall 39% protection against HIV in partici-
pants of the CAPRISA 004 study, a randomized controlled
trial of tenofovir gel versus placebo in young African women
[42]. However, gel efficacy varied significantly with adher-
ence (54% reduction in HIVacquisition with > 80% adherence
but 28% efficacy in those with < 50% adherence). Women
younger than 25 years of age had the greatest HIVacquisition
risk and the lowest plasma TFV levels, which could reflect
poor adherence as well as variability in drug uptake and me-
tabolism [30].
Intravaginal rings (IVRs) are marketed for contraception in
adolescents, and a ring designed to deliver the antiretroviral
drug dapivirine has been tested in two concurrent phase 3
trials and found to be modestly efficacious at reducing HIV
risk (27% in ASPIRE trial, 31% in The Ring Study) [43, 44].
In the ASPIRE trial, age disparities in efficacy were found.
Women ages 22–45 using the dapivirine ring had 56% fewer
infections than those in the placebo arm. However, the ring
actually showed no protection among younger women ages
18–21, who used the ring least regularly. Interestingly, in the
TRIO study described earlier, the ring was the product that
young women were least familiar with [41].
Finally, those at high risk of HIV acquisition through anal
sex could benefit from availability of a rectal microbicide.
Research with MSM and transgender women has demonstrat-
ed safety and acceptability of rectal use of TFV gel [45];
however, adherence was higher in event driven use than daily
use suggesting the need for convenient dosing regimens [46].
Male Circumcision
Male circumcision has been proven to significantly reduce the
risk of HIV acquisition. Three RCTs showed an HIV protec-
tion effect of 60% for men who are circumcised which is
equivalent to what a reasonable vaccine would offer in terms
of both efficacy and sustainability of protection coverage and
the circumcision procedure is inexpensive and quick to per-
form [47–49]. VMMC has been a recommended component
of HIV prevention packages by the WHO since 2007 with the
goal of increasing coverage among males ages 10–29 to 90%
by 2021 [50]. Indeed, an impressive scale up of VMMC has
occurred among priority countries in Eastern and Southern
Africa, with the majority of clients aged 15 years or older
[51]. Unfortunately, a recent modeling paper highlights that
the WHO goal of 90% coverage will only be reached with
significant increases in the number of circumcisions provided
to adolescents ages 10–14 [52]. Furthermore, significant age
differences have been found in the HIV prevention counseling
content that is received by adolescents regarding VMMC,
with older adolescents (15–19 years old) receiving more com-
prehensive information than those ages 10–14, largely due to
the discomfort that counselors, providers, and parents have
with adolescent sexuality [53].
Behavioral HIV Prevention Interventions
The 2018 CDC Compendium of Evidence-Based
Interventions and Best Practices for HIV Prevention recog-
nizes 61 behavioral interventions in the HIV risk reduction
c h a p t e r ( h t t p s : / / www. c d c . g o v / h i v / r e s e a r c h /
interventionresearch/compendium/rr/index.html). Of those
that were specifically designed for and tested among
adolescents (n = 15), 8 were classified as “best evidence”
(i.e., rigorously evaluated and shown to have significant
evidence of efficacy to eliminate or HIV risk behaviors,
reduce the rate of new HIV/STD infections, or increase HIV-
protective behaviors).
Several recent systematic literature reviews also highlight
the paucity of rigorously evaluated behavioral interventions
for youth as well as the relative absence of interventions ex-
clusively designed for adolescents. Hergenrather and col-
leagues [54] reviewed behavioral interventions for young
MSM and found 15 interventions targeting YMSM in the
age range of 13–24. Of note, none of interventions focused
on adolescents alone and several included young people up
through the age of 29. A recent review of behavioral HIV
prevention interventions for adolescents in sub-Saharan
Africa yielded a total of 8 with significant outcomes in both
knowledge and sexual behavior [55]. Finally, a review of rig-
orously tested (e.g., randomized controlled trial), technology-
based, behavioral HIV prevention interventions for Black, and
Latino youth identified only 2 studies [56]. Thus, the quantity,
and perhaps the quality, of HIV prevention interventions
targeting adolescents in general are limited.
Promising new behavioral interventions continue to be de-
veloped and tested among youth at greatest risk for HIV in-
fection. Garofalo and colleagues [57] recently published data
from a randomized controlled trial of a group delivered HIV
prevention intervention for transgender young women. The
intervention, LifeSkills, demonstrated a 40% larger reduction
in condomless sex acts compared to an attention-matched
control group at the 12-month follow-up point. This success
makes LifeSkills the first behavioral HIV prevention interven-
tion specifically designed for transgender youth to show effi-
cacy. For young Black MSM, the newly tes ted
healthMpowerment intervention reported promising results
[58]. Participants assigned to healthMpowerment, a mobile
phone optimized, internet-based intervention, demonstrated a
38% reduction in condomless anal intercourse compared to
the control group. Furthermore, intervention participants re-
ported decreases in perceived HIV stigma over time [59].
While there remains a paucity of HIV prevention inter-
ventions for adolescents, newer and more cost-effective ap-
proaches to test ing and implementing behavioral
interventions are needed. Just as we know that trials de-
signed for one particular group do not necessarily translate
to other groups, we also need to recognize that not every
individual within a population needs the same intervention.
In order to study varied approaches to intervention imple-
mentation, adaptive clinical trial designs can be used that
prospectively plan opportunities for modification of one or
more specified aspects of the study design and hypotheses
based on analysis of data (usually interim data) from partic-
ipants in the study [60]. Adaptive trial designs can also
improve trial efficiency by potentially decreasing the dura-
tion of the trial and enrolling fewer participants [61].
Finally, the most impactful and scalable implementation
approaches for behavioral interventions may well be to use
them in conjunction with biomedical interventions. As de-
scribed above, behavioral interventions for young people have
been proven to reduce HIV/sexually transmitted infection
(STI) risk by increasing condom use, reducing or delaying
frequencies of sex, and increasing safer sex negotiation skills.
However, many behavioral interventions have limitations in-
cluding only moderate levels of efficacy and few available
resources to bring multi-session approaches to scale [62].
The series of Adolescent Trials Network (ATN) PrEP studies
incorporated evidence-based behavioral HIV prevention inter-
ventions, which may have led to the declines in sexual risk
behavior seen among participants [31, 63–65]. However, the
most impactful type of behavioral intervention needed for
participants may have been one focused on improving PrEP
adherence and persistence. Thus, finding the right mix of be-
havioral and biomedical to produce the greatest prevention
impact is still critical.
Structural HIV Prevention Interventions
It is increasingly clear that structural drivers of HIV infection
play an important role in increasing HIV risk for adolescents.
Factors such as poverty, limited education, unemployment,
food insecurity, violence, stigma, and discrimination not only
increase the risk of HIV acquisition but also limit access to
prevention and care interventions. While there is still a great
need for a larger evidence base of effective structural interven-
tions for HIV prevention, there has been some progress made
in the areas of social protection and gender-based violence.
A number of recent trials have been conducted examin-
ing the role of cash transfers in reducing HIV risk for young
women in sub-Saharan Africa. The first study, HPTN 068,
provided monthly cash transfers to South African adoles-
cent girls and young women (AGYW) and their parent/
guardian conditional on 80% school attendance. The trial
found no impact of the cash on HIV incidence or school
attendance which was very high in both arms over the
3 years of the trials (95%); however, there were significant
reductions in physical violence from a partner and
reductions in unprotected sex and partner number [66].
Additionally, the study found that AGYWs who did drop
out of school or have low attendance were at substantially
increased risk of acquiring HIV infections (HR 3.25 95% CI
95% CI 1.67, 6.32) [67]. Another cash transfer trial among
high school girls and boys in South Africa also found no
effect on HIV incidence [68]. While these studies looking at
HIV incidence have found no impact, a trial conducted in
Malawi did find that a small cash transfer provided to
AGYW and their parent/guardian resulted in lower HIV
prevalence in the intervention arm compared to those not
getting the cash and were less likely to have an older partner
and to have had frequent sex [69]. Additionally, observa-
tional studies looking at the effect of large, government cash
transfer programs on adolescent HIV risk behavior have
found that adolescents living in homes receiving the transfer
were less likely to report engaging in transactional sex and
having an older partner [70] and were more likely to delay
coital debut [71]. Research by Cluver and colleagues on the
South African social protection program has found that for
adolescents living in homes receiving social protection plus
additional forms of care the HIV prevention effects seem
much stronger [72]. Given this finding, and the null effects
on HIV acquisition, there is current consensus that social
protection, in particular cash transfers, should be combined
with other interventions for maximal impact on HIV pre-
vention. In a model developed by Roelen and colleagues
[73], they posit that forms of cash plus could include psy-
chosocial support, additional social benefits, information
and behavior change interventions, and provision or linkage
to services, including health services. As of July 2018, there
are a number of cash plus trials in the field examining the
impact of combining cash with other programs for HIV pre-
vention among AGYW. The DREAMS program which is a
large PEPFAR prevention program to reduce HIV among
AGYWin ten countries in Africa has cash transfer programs
active as part of a larger combination prevention program in
some of the countries (http://www.dreamspartnership.org/).
In Cape Town, South Africa, the Global Fund is providing
funding for a cash plus intervention trial (Women of Worth)
to reduce HIV risk among AGYW (http://desmondtutuhiv
foundation.org.za/zimele/) and UNICEF is conducting an




The mechanisms whereby cash transfers may reduce HIV
risk are primarily thought to be through increased resources
which improve access to school, improve mental health/hope
for the future, and reduce reliance on partners/transactional
sex. To date, there is some evidence to support all of these
pathways; however, for the transactional sex pathways, it is
important to note that transactional sex is a complex behavior
which is not always driven solely by poverty [74]. Qualitative
research with AGYW about transactional sex in Southern
Africa has found that AGYW often engage in transactional
sex as a means to obtain social status among peers and luxury
items to gain self-esteem and worth, particularly in settings
where employment opportunities for young women are ex-
tremely limited [75, 76]. Small cash transfers will likely not
be able to overcome these needs and desires and prevent trans-
actional sex and thus programs to build self-esteem, improve
access to HIV prevention services, and other life skills are
likely necessary for impact.
Interventions to reduce gender-based violence are also crit-
ical for prevention. Intimate partner violence (IPV) rates
among adolescents in many settings where HIV prevalence
is endemic are very high. Among adolescent girls in South
Africa, 24–40% of adolescent girls report having experienced
physical violence from a partner and 8–15% sexual violence
[77, 78]. Recent PrEP trials have found that violence from
partners was associated with low adherence to the drug [79].
While the evidence base for interventions to reduce IPV
among adolescents as part of HIV prevention are somewhat
limited, there are a number of trials that have included indi-
viduals 15 and older and have been successful in reducing IPV
perpetration and victimization in Southern Africa [80, 81].
Recently, community mobilization has been employed as a
tool to change community norms around gender-based vio-
lence with the goal of reducing IPV, both the SASA commu-
nity mobilization intervention trial in Uganda [82, 83] and the
SHARE trial in Uganda [84] found significant reductions in
the acceptability of IPV among men and women and lower
levels of women reporting physical and sexual violence vic-
timization, although the results in the SASA trial were not
statistically significant.
The Inclusion of Adolescent Minors in Clinical Trials
Historically, medical treatments applied to children were often
based upon testing done only in adults, rendering evidence-
based treatments less available to children due to their exclu-
sion from studies. Since 1996, one goal of the National
Institutes of Health as well as the US FDA has been to increase
the participation of children in research so that adequate data
can be developed to support treatment (and prevention) modal-
ities for disorders and conditions that affect adults as well as
children. In order for adolescents to access safe and effective
new biomedical HIV prevention products at the same time that
these products are approved and marketed for adults, the scien-
tific development and testing of these products for adolescents
must proceed concurrently [85]. Similarly, adolescents are often
excluded from behavioral and structural intervention trials due
to concerns from regulatory or ethics boards as well as investi-
gator concerns around the complexity of recruitment/retention
and/or fear that adolescent difficulties will adversely impact the
primary outcomes of the trial [86, 87]. Unfortunately, exclusion
from larger trials as well as hesitancy to launch youth-focused
trials only exacerbates the gaps in HIV prevention intervention
availability and access, which continues to fuel the HIV
epidemic among vulnerable young people.
Conclusion
As adolescents transition to adulthood, there are numer-
ous changes occurring in their lives that make context a
critical consideration for prevention interventions. An 18-
year-old student who is living at home with their parents
may have very different prevention needs than an 18 years
old who has a child and is living with a partner.
Prevention programs must acknowledge that adolescents
are influenced by peers, family, and community. Recent
failures to reduce HIV incidence in AGYW or to increase
uptake of new prevention technologies among key popu-
lations can be partly attributed to the influential role that
partners, family, and communities play in the lives of
youth [36, 79, 88]. We must also acknowledge that as
adolescents learn to use prevention interventions, they
will make mistakes and will need support. This is not a
failure of prevention programs per se, but an acknowl-
edgement for the field that behavior change takes time,
depends on context, and is a process.
Ultimately, young people will benefit from a range of pre-
vention interventions. Currently, there is a need to increase
access and adherence to existing efficacious prevention inter-
ventions but there is also great need for an increase in the
number of biologic, behavioral, and structural intervention
options that are appropriate for adolescents and young people.
Importantly, we must truly embrace the message that adoles-
cent and young people are not a homogenous population and
will need tailored approaches to meet their needs.
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